Doctors

消化器内科学教室 スタッフ紹介

助教併任 Assistant Professor
瀬古 裕也 Yuya Seko, M.D., Ph.D.

出身地 京都府

略 歴

2008年 京都府立医科大学医学部医学科卒業
国立国際研究センター内科研修医
2010年 国家公務員共済組合連合会虎の門病院肝臓センター 医員
2013年 京都府立医科大学大学院医学研究科 消化器内科学 入学
2016年 京都府立医科大学大学院医学研究科 消化器内科学 修了
2016年 京都府健康福祉部健康対策課・医療課 医務主幹
京都府立医科大学消化器内科 助教(併任)
2020年 京都府立医科大学消化器内科 助教
現在に至る

専 門

  • 消化器病学
  • 肝臓病学
  • NAFLD/NASH

所属学会

  • 日本内科学会総合内科専門医
  • 日本消化器病学会専門医 学会評議員
  • 日本肝臓学会専門医 西部会評議員

業 績

  1. Seko Y, Moriguchi M, Itoh Y, et al. Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents. J Gastroenterol. 2022 Feb;57(2):90-98.
  2. Kamada Y, Sumida Y, Seko Y, Nakajima A, Okanoue T et al.; Japan Study Group of NAFLD (JSG‐NAFLD). Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review.  J Gastroenterol. 2021 Dec;56(12):1045-1061.
  3. Sumida Y, Seko Y, Okanoue T, et al.; Japan Study Group of NAFLD (JSG-NAFLD). Role of vitamin E in the treatment of non-alcoholic steatohepatitis. Free Radic Biol Med. 2021 Dec;177:391-403.
  4. Ito T, Ishigami M, Seko Y, Nguyen MH, et al. The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040. Hepatol Int. 2021 Apr;15(2):366-379.
  5. Seko Y, Yamaguchi K, Itoh Y, et al. The Effect of Genetic Polymorphism in Response to Body Weight Reduction in Japanese Patients with Nonalcoholic Fatty Liver Disease. Genes (Basel). 2021 Apr 22;12(5):628.
  6. Seko Y, Yano K, Itoh Y, et al. The Appropriate Opportunity for Evaluating Liver Fibrosis by Using the FIB-4 Index in Patients with Nonalcoholic Fatty Liver Disease in Japan. Diagnostics (Basel) (IF: 5.25; Q2). 2020 Oct 19;10(10):842.
  7. Seko Y, Yamaguchi K, Itoh Y, et al. Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: A single-arm, pilot study. Hepatol Res. 2020 Dec;50(12):1328-1336.
  8. Seko Y, Yamaguchi K, Tochiki N, Yano K, Takahashi A, Okishio S, Kataoka S, Okuda K, Umemura A, Moriguchi M, Tanaka S, Mori K, Okanoue T, Itoh Y. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease. Liver Int. 2020 Jul;40(7):1686-1692.
  9. Yano K, Seko Y, Itoh Y, et al. Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan. Diagnostics (Basel). 2020 Feb 6;10(2):86.
  10. Taylor RS, Taylor RJ, Bayliss S, Hagström H, Nasr P, Schattenberg JM, Ishigami M, Toyoda H, Wai-Sun Wong V, Peleg N, Shlomai A, Sebastiani G, Seko Y, Bhala N, Younossi ZM, Anstee QM, McPherson S, Newsome PN. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology. 2020 May;158(6):1611-1625.
  11. Seko Y, Yano K, Itoh Y, et al. FIB-4 Index and Diabetes Mellitus Are Associated with Chronic Kidney Disease in Japanese Patients with Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2019 Dec 25;21(1):171.
  12. Seko Y, Mizuno N, Itoh Y, et al. Clinical and pathological features of sarcopenia-related indices in patients with non-alcoholic fatty liver disease. Hepatol Res. 2019 Jun;49(6):627-636.
  13. Seko Y, Moriguchi M, Itoh Y, et al. Presence of varices in patients after hepatitis C virus eradication predicts deterioration in the FIB-4 index. Hepatol Res. 2019 ;49(4):473-478.
  14. Mizuno N, Seko Y, Itoh Y, et al. Increase in the skeletal muscle mass to body fat mass ratio predicts the decline in transaminase in patients with nonalcoholic fatty liver disease. J Gastroenterol. 2019 ;54(2):160-170.
  15. Itoh Y, Seko Y, Okanoue T, et al. Accuracy of non-invasive scoring systems for diagnosing non-alcoholic steatohepatitis-related fibrosis: Multicenter validation study. Hepatol Res. 2018 ;48(13):1099-1107.
  16. Seko Y, Nishikawa T, Itoh Y, et al. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis. Diabetes Metab Syndr Obes. 2018 ;27;11:835-843.
  17. Seko Y, Sumida Y, Inagaki N, et al. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. J Gastroenterol. 2018 ;53(1):140-151.
  18. Seko Y, Yamaguchi K, Itoh Y, et al. Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease. J Gastroenterol. 2018 ;53(3):438-448.
  19. Seko Y, Sumida Y, Itoh Y, et al. Insulin resistance increases the risk of incident type 2 diabetes mellitus in patients with non-alcoholic fatty liver disease. Hepatol Res. 2018 ;48(3):E42-E51.
  20. Seko Y, Sumida Y, Itoh Y, et al. Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res. 2017 ;47(11):1206-1211.
  21. Seko Y, Sumida Y, Itoh Y, et al. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res. 2017 ;47(10):1072-1078.
  22. Seko Y, S umida Y, Itoh Y, et al. Development of hepatocellular carcinoma in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: in relation to PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression. Hepatol Res. 2017 ;47(11):1083-1092.
  23. Seko Y, Sumida Y, Itoh Y, et al. Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res. 2015 ;45(10):E53-61.
  24. Seko Y, Sumida Y, Itoh Y, et al. Predictors of malignancies and overall mortality in Japanese patients with biopsy-proven non-alcoholic fatty liver disease. Hepatol Res. 2015 ;45(7):728-38.
  25. Seko Y, Ikeda K, Kumada H, et al. Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma. Hepatol Res. 2013 ;43(9):942-9.
  26. Seko Y, Akuta N, Kumada H, et al. Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy. Intervirology. 2013;56(1):13-21.

お問い合わせ
〒602-8566 京都市上京区河原町通広小路上る梶井町465番地 京都府立医科大学消化器内科
TEL:075-251-5519(医局)FAX:075-251-0710(医局)消化器内科医局 mail: s-ikyoku@koto.kpu-m.ac.jp